IGF-1 LR3
A modified insulin-like growth factor 1 variant engineered for an extended half-life and reduced binding-protein interference.
Research status: Studied in muscle-growth and recovery research contexts.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
Selected references
- Biochemical Journal · 1992 Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats
- Journal of Endocrinology · 1996 Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection
- Journal of Endocrinology · 1995 Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig
- American Journal of Pathology · 2011 IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.
Related in Growth Factor